Evidence mapPaperPMID 28096223Full record

Trial reportDiabetes care2017

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.

Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, John Adams, Curtis Triplitt, Ralph A DeFronzo, Mahmoud Zirie, Amin Jayyousi

Erratum issued 2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03658031 phase3unknown statusstarted 2019, after this paper: background citation

Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

Ran2019Enrolled576Registered outcomes1Posted comparisons0ConditionsCVD, Myocardial Infarction, Prediabetes, T2DM (Type 2 Diabetes Mellitus)ArmsDapagliflozin 10mg
Open the trial in the graph
NCT03794518 phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Effect of Combination Therapy With Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

TypeinterventionalSponsorHamad Medical CorporationRan2019 to 2021Enrolled648ConditionsRisk ReductionArmsPioglitazone Plus dapaglifliozin, Placebo
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Muhammad Abdul-GhaniDiabetes Research, Academic Health System, Hamad General Hospital, Doha, Qatar abdulghani@uthscsa.edu.
Osama MigahidDiabetes Research, Academic Health System, Hamad General Hospital, Doha, Qatar.
Ayman MegahedDiabetes Research, Academic Health System, Hamad General Hospital, Doha, Qatar.
John AdamsDivision of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Curtis TriplittDivision of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Ralph A DeFronzoDivision of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Mahmoud ZirieDiabetes Research, Academic Health System, Hamad General Hospital, Doha, Qatar.
Amin JayyousiDiabetes Research, Academic Health System, Hamad General Hospital, Doha, Qatar.
Hamad General Hospital · QAThe University of Texas Health Science Center at San Antonio · US

Funding

NIDDK NIH HHS R01 DK103841
6 · The paper itself

Abstract

objectiveThe Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea. RESEARCH DESIGN AND

methodsThe study randomized 231 patients with poorly controlled (HbA

resultsAfter a mean follow-up of 12 months, combination therapy caused a robust decrease in HbA

conclusionsCombination exenatide/pioglitazone therapy is a very effective and safe therapeutic option in patients with long-standing poorly controlled T2DM on metformin plus a sulfonylurea.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Drug Therapy, CombinationExenatideFemaleFollow-Up StudiesGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinMaleMetforminMiddle AgedPeptidesPioglitazoneBlood GlucoseExenatideGlycated HemoglobinHypoglycemic AgentsInsulinMetforminPeptidesPioglitazoneSulfonylurea CompoundsThiazolidinedionesVenoms

Identifiers

PMID28096223
PMCPMC5864032
OpenAlexW2572847517

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.